Scroll

brimonidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
alpha-2 adrenoreceptor agonists	395	59803-98-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: UK 14,304 mirvaso brimonidine brimonidine tartrate bromoxidine	A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. Molecular weight: 292.14 Formula: C11H10BrN5 CLOGP: 1.49 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 62.20 ALOGS: -3.28 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

UK 14,304
mirvaso
brimonidine
brimonidine tartrate
bromoxidine

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Molecular weight: 292.14
Formula: C11H10BrN5
CLOGP: 1.49
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 62.20
ALOGS: -3.28
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1.50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Show entries

Search:

Date	Agency	Company
Feb. 20, 2014	EMA	GALDERMA INTERNATIONAL
March 25, 2020	PMDA	Senju Pharmaceutical Co., Ltd
Sept. 6, 1996	FDA

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	477.58	17.46	332	9995	198711	63279984
Eye irritation	430.23	17.46	154	10173	21817	63456878
Ocular hyperaemia	417.26	17.46	156	10171	24988	63453707
Intraocular pressure increased	400.45	17.46	108	10219	5970	63472725
Eye pain	240.57	17.46	115	10212	33739	63444956
Corneal opacity	135.60	17.46	30	10297	713	63477982
Iridocyclitis	130.05	17.46	37	10290	2485	63476210
Vision blurred	122.91	17.46	109	10218	91815	63386880
Eye pruritus	110.38	17.46	56	10271	18615	63460080
Glaucoma	101.09	17.46	53	10274	18852	63459843

Showing 1 to 10 of 87 entries

Previous1 2 3 4 5…9Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	537.41	18.80	233	6519	46464	34903715
Intraocular pressure increased	395.35	18.80	108	6644	5275	34944904
Ocular hyperaemia	242.61	18.80	89	6663	11363	34938816
Eye irritation	222.27	18.80	75	6677	7486	34942693
Corneal oedema	166.72	18.80	41	6711	1310	34948869
Eye pain	128.03	18.80	59	6693	13403	34936776
Visual acuity reduced	123.74	18.80	61	6691	16088	34934091
Ocular surface disease	123.36	18.80	20	6732	60	34950119
Choroidal detachment	112.57	18.80	24	6728	398	34949781
Corneal opacity	94.08	18.80	22	6730	564	34949615

Showing 1 to 10 of 63 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	579.75	16.20	156	12124	9049	79723059
Ocular hyperaemia	354.80	16.20	141	12139	28065	79704043
Eye irritation	315.60	16.20	119	12161	20562	79711546
Corneal oedema	235.67	16.20	59	12221	2561	79729547
Eye pain	205.52	16.20	105	12175	37473	79694635
Ocular surface disease	183.73	16.20	29	12251	94	79732014
Visual acuity reduced	171.81	16.20	86	12194	29383	79702725
Vision blurred	150.48	16.20	127	12153	105771	79626337
Blepharitis	107.06	16.20	33	12247	3091	79729017
Foreign body sensation in eyes	105.47	16.20	30	12250	2127	79729981

Showing 1 to 10 of 108 entries

Previous1 2 3 4 5…11Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	D11AX21	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals
ATC	S01EA05	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Sympathomimetics in glaucoma therapy
ATC	S01GA07	SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Sympathomimetics used as decongestants
CHEBI has role	CHEBI:35569	alpha-adrenergic agonists
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37886	adrenergic agonists
FDA EPC	N0000175552	alpha-Adrenergic Agonist
FDA MoA	N0000000209	Adrenergic alpha-Agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists

Showing 1 to 10 of 15 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067
Rosacea	indication	398909004	DOID:8881
Bronchospasm	contraindication	4386001
Complete atrioventricular block	contraindication	27885002
Orthostatic hypotension	contraindication	28651003
Acute cerebrovascular insufficiency	contraindication	29322000
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Anaphylaxis	contraindication	39579001

Showing 1 to 10 of 25 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.64	Basic
pKa2	1.82	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.025%	LUMIFY	BAUSCH AND LOMB INC	N208144	Dec. 22, 2017	OTC	SOLUTION/DROPS	OPHTHALMIC	11596600	July 27, 2029	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
0.025%	LUMIFY	BAUSCH AND LOMB INC	N208144	Dec. 22, 2017	OTC	SOLUTION/DROPS	OPHTHALMIC	8293742	July 14, 2030	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
0.025%	LUMIFY	BAUSCH AND LOMB INC	N208144	Dec. 22, 2017	OTC	SOLUTION/DROPS	OPHTHALMIC	9259425	July 14, 2030	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	8859551	May 25, 2024	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	8410102	May 24, 2025	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	8426410	May 24, 2025	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	7439241	Aug. 25, 2025	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	8513247	March 25, 2031	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	8513249	March 25, 2031	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
EQ 0.33% BASE	MIRVASO	GALDERMA LABS LP	N204708	Aug. 23, 2013	RX	GEL	TOPICAL	9861631	March 25, 2031	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Showing 1 to 10 of 12 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	AGONIST	EC50	8.47	WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	AGONIST	EC50	8.39	WOMBAT-PK	CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	AGONIST	EC50	7.26	WOMBAT-PK	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	5.27	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	5.55	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.84	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.07	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT		Ki	7.28	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.59	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		EC50	5.95	CHEMBL

Showing 1 to 10 of 13 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
J59	PDB_CHEM_ID
006196	NDDF
006197	NDDF
108827001	SNOMEDCT_US
134615	RXNORM
14807	MMSL
205316	MMSL
240890	MMSL
2435	PUBCHEM_CID
31659	MMSL

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ALPHAGAN P	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9177	SOLUTION/ DROPS	1.50 mg	OPHTHALMIC	NDA	25 sections
ALPHAGAN P	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9177	SOLUTION/ DROPS	1.50 mg	OPHTHALMIC	NDA	25 sections
ALPHAGAN P	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9321	SOLUTION/ DROPS	1 mg	OPHTHALMIC	NDA	25 sections
ALPHAGAN P	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9321	SOLUTION/ DROPS	1 mg	OPHTHALMIC	NDA	25 sections
Brimonidine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-715	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	25 sections
Brimonidine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-715	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	25 sections
BRIMONIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	45802-078	GEL	5 mg	TOPICAL	ANDA	26 sections
Brimonidine Tartrate	Human Prescription Drug Label	1	14445-400	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	24 sections
BRIMONIDINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-883	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	12 sections
Brimonidine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-411	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	22 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next